[ CAS No. 13754-19-3 ] {[proInfo.proName]}

Name: 13754-19-3|Pyrimidine-4,5-diamine|97%
Brand: Ambeed
SKU: A203964
Price: 10.0 USD
Availability: InStock
Rating: 99 (32 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 13754-19-3

Structure of 13754-19-3 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 13754-19-3 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 13754-19-3 ]

SDS Specification

Alternatived Products of [ 13754-19-3 ]

Product Details of [ 13754-19-3 ]

CAS No. :	13754-19-3	MDL No. :	MFCD00006113
Formula :	C₄H₆N₄	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	PPAULTVPKLVLII-UHFFFAOYSA-N
M.W :	110.12	Pubchem ID :	83703
Synonyms :

Calculated chemistry of [ 13754-19-3 ]

Physicochemical Properties

Num. heavy atoms :	8
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.0
Num. rotatable bonds :	0
Num. H-bond acceptors :	2.0
Num. H-bond donors :	2.0
Molar Refractivity :	30.84
TPSA :	77.82 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	No
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-7.56 cm/s

Lipophilicity

Log Po/w (iLOGP) :	0.68
Log Po/w (XLOGP3) :	-0.83
Log Po/w (WLOGP) :	-0.34
Log Po/w (MLOGP) :	-1.31
Log Po/w (SILICOS-IT) :	-0.37
Consensus Log Po/w :	-0.43

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	2.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-0.55
Solubility :	30.7 mg/ml ; 0.279 mol/l
Class :	Very soluble
Log S (Ali) :	-0.32
Solubility :	52.2 mg/ml ; 0.474 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-0.87
Solubility :	14.8 mg/ml ; 0.134 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.55

Safety of [ 13754-19-3 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 13754-19-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 13754-19-3 ]
Downstream synthetic route of [ 13754-19-3 ]

[ 13754-19-3 ] Synthesis Path-Upstream 1~21

1
[ 13754-19-3 ]
[ 64-19-7 ]
[ 934-33-8 ]

Reference： [1] Organic Letters, 2013, vol. 15, # 14, p. 3794 - 3797

2
[ 13754-19-3 ]
[ 108-24-7 ]
[ 934-33-8 ]

Reference： [1] Chemische Berichte, 1906, vol. 39, p. 252
[2] Journal of the Chemical Society, 1954, p. 2060,2062
[3] Journal of the Chemical Society, 1954, p. 2060,2062

3
[ 4316-98-7 ]
[ 13754-19-3 ]

Reference： [1] Journal of the American Chemical Society, 1954, vol. 76, p. 6073,6076

4
[ 14631-08-4 ]
[ 13754-19-3 ]

Reference： [1] Nature (London, United Kingdom), 1948, vol. 162, p. 524

5
[ 1920-66-7 ]
[ 13754-19-3 ]

Reference： [1] Chemische Berichte, 1906, vol. 39, p. 252

6
[ 14623-58-6 ]
[ 13754-19-3 ]

Reference： [1] Journal of Applied Chemistry, 1952, vol. 2, p. 239
[2] Journal of the Chemical Society, 1951, p. 474,478[3] Journal of the Chemical Society, 1952, p. 4219,4224

7
[ 78105-09-6 ]
[ 13754-19-3 ]
[ 934-33-8 ]

Reference： [1] Acta Chemica Scandinavica, Series B: Organic Chemistry and Biochemistry, 1982, vol. 36, # 10, p. 707 - 712

8
[ 16008-45-0 ]
[ 13754-19-3 ]
[ 120-73-0 ]

Reference： [1] Journal of Organic Chemistry, 1984, vol. 49, # 25, p. 4964 - 4969

9
[ 93135-56-9 ]
[ 13754-19-3 ]
[ 532-20-7 ]

Reference： [1] Journal of Organic Chemistry, 1984, vol. 49, # 25, p. 4964 - 4969

10
[ 16008-45-0 ]
[ 13754-19-3 ]
[ 64-18-6 ]
[ 120-73-0 ]

Reference： [1] Acta Chemica Scandinavica, Series B: Organic Chemistry and Biochemistry, 1984, vol. 38, # 8, p. 673 - 678

11
[ 95103-63-2 ]
[ 13754-19-3 ]
[ 934-33-8 ]

Reference： [1] Acta Chemica Scandinavica, Series B: Organic Chemistry and Biochemistry, 1984, vol. 38, # 7 B, p. 573 - 578

12
[ 78105-09-6 ]
[ 13754-19-3 ]
[ 934-33-8 ]

Reference： [1] Acta Chemica Scandinavica, Series B: Organic Chemistry and Biochemistry, 1984, vol. 38, # 7 B, p. 573 - 578

13
[ 95103-62-1 ]
[ 13754-19-3 ]
[ 934-33-8 ]

Reference： [1] Acta Chemica Scandinavica, Series B: Organic Chemistry and Biochemistry, 1984, vol. 38, # 7 B, p. 573 - 578

14
[ 95103-65-4 ]
[ 13754-19-3 ]
[ 934-33-8 ]

Reference： [1] Acta Chemica Scandinavica, Series B: Organic Chemistry and Biochemistry, 1984, vol. 38, # 7 B, p. 573 - 578

15
[ 550-33-4 ]
[ 13754-19-3 ]
[ 532-20-7 ]
[ 120-73-0 ]

Reference： [1] Acta Chemica Scandinavica, Series B: Organic Chemistry and Biochemistry, 1984, vol. 38, # 8, p. 673 - 678

16
[ 13754-19-3 ]
[ 623-50-7 ]
[ 934-33-8 ]

Reference： [1] Patent: US5624935, 1997, A,

17
[ 78105-09-6 ]
[ 13754-19-3 ]
[ 934-33-8 ]

Reference： [1] Acta Chemica Scandinavica, Series B: Organic Chemistry and Biochemistry, 1982, vol. 36, # 10, p. 707 - 712

18
[ 95103-63-2 ]
[ 13754-19-3 ]
[ 934-33-8 ]

Reference： [1] Acta Chemica Scandinavica, Series B: Organic Chemistry and Biochemistry, 1984, vol. 38, # 7 B, p. 573 - 578

19
[ 78105-09-6 ]
[ 13754-19-3 ]
[ 934-33-8 ]

Reference： [1] Acta Chemica Scandinavica, Series B: Organic Chemistry and Biochemistry, 1984, vol. 38, # 7 B, p. 573 - 578

20
[ 95103-62-1 ]
[ 13754-19-3 ]
[ 934-33-8 ]

Reference： [1] Acta Chemica Scandinavica, Series B: Organic Chemistry and Biochemistry, 1984, vol. 38, # 7 B, p. 573 - 578

21
[ 95103-65-4 ]
[ 13754-19-3 ]
[ 934-33-8 ]

Reference： [1] Acta Chemica Scandinavica, Series B: Organic Chemistry and Biochemistry, 1984, vol. 38, # 7 B, p. 573 - 578

[ 13754-19-3 ] Synthesis Path-Downstream 1~88

1
[ 123-91-1 ]
[ 290-87-9 ]
[ 13754-19-3 ]
[ 120-73-0 ]

Reference： [1]Journal of the American Chemical Society,1955,vol. 77,p. 6559

2
[ 290-87-9 ]
[ 13754-19-3 ]
[ 68-12-2 ]
[ 120-73-0 ]

Reference： [1]Journal of the American Chemical Society,1955,vol. 77,p. 6559

3
[ 290-87-9 ]
[ 13754-19-3 ]
[ 71-43-2 ]
[ 120-73-0 ]

Reference： [1]Journal of the American Chemical Society,1955,vol. 77,p. 6559

4
[ 290-87-9 ]
[ 13754-19-3 ]
[ 120-73-0 ]

Reference： [1]Journal of the American Chemical Society,1955,vol. 77,p. 6559
[2]Journal of the American Chemical Society,1955,vol. 77,p. 6559

5
[ 14631-08-4 ]
[ 13754-19-3 ]

Reference： [1]Nature,1948,vol. 162,p. 524

6
[ 4316-98-7 ]
[ 13754-19-3 ]

Reference： [1]Journal of the American Chemical Society,1954,vol. 76,p. 6073,6076

7
[ 14623-58-6 ]
[ 13754-19-3 ]

Reference： [1]Journal of Applied Chemistry,1952,vol. 2,p. 239

8
[ 1920-66-7 ]
[ 13754-19-3 ]

Reference： [1]Chemische Berichte,1906,vol. 39,p. 252

9
[ 617-35-6 ]
[ 13754-19-3 ]
[ 1128-60-5 ]
[ 16041-30-8 ]

Reference： [1]Journal of Heterocyclic Chemistry,1992,vol. 29,p. 1279 - 1283

10
[ 617-35-6 ]
[ 13754-19-3 ]
[ 16041-30-8 ]

Reference： [1]Journal of Heterocyclic Chemistry,1992,vol. 29,p. 1279 - 1283

11
[ 13754-19-3 ]
[ 7478-57-1 ]
[ 86475-09-4 ]

Reference： [1]Journal of Heterocyclic Chemistry,1983,vol. 20,p. 359 - 364

12
[ 13754-19-3 ]
[ 7478-57-1 ]
[ 86475-08-3 ]

Reference： [1]Journal of Heterocyclic Chemistry,1983,vol. 20,p. 359 - 364

13
[ 13754-19-3 ]
[ 7478-57-1 ]
[ 138196-65-3 ]

Reference： [1]Journal of Heterocyclic Chemistry,1991,vol. 28,p. 1501 - 1510

14
[ 13754-19-3 ]
[ 574-17-4 ]
[ 93065-32-8 ]

Reference： [1]Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry,1984,vol. 23,p. 114 - 116

15
[ 13754-19-3 ]
[ 816-27-3 ]
[ 1822-20-4 ]

Reference： [1]Tetrahedron Letters,1982,vol. 23,p. 3357 - 3360
[2]Synthesis,1997,p. 301 - 304

16
[ 13754-19-3 ]
[ 685-24-5 ]
6,7-bis(trifluoromethyl)-5,6,7,8-tetrahydropteridine-6,7-diol [ No CAS ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1986,p. 1043 - 1050

17
[ 13754-19-3 ]
[ 3984-34-7 ]
8a-(4'-Chlorophenyl)-7,8,8a,9-tetrahydro-6H-pyrrolo<2,1-f>purin-6-one [ No CAS ]

Reference： [1]Il Farmaco,1993,vol. 48,p. 1261 - 1269

18
[ 13754-19-3 ]
[ 91-52-1 ]
[ 95420-68-1 ]

Reference： [1]Journal of Medicinal Chemistry,1985,vol. 28,p. 717 - 727

19
[ 13754-19-3 ]
[ 19972-69-1 ]
[ 128587-32-6 ]

Reference： [1]Journal of Heterocyclic Chemistry,1990,vol. 27,p. 221 - 226

20
[ 13754-19-3 ]
[ 19972-68-0 ]
[ 128587-34-8 ]

Reference： [1]Journal of Heterocyclic Chemistry,1990,vol. 27,p. 221 - 226

21
[ 13754-19-3 ]
[ 19972-70-4 ]
[ 128587-33-7 ]

Reference： [1]Journal of Heterocyclic Chemistry,1990,vol. 27,p. 221 - 226

22
[ 13754-19-3 ]
[ 31616-72-5 ]
[ 82272-27-3 ]

Reference： [1]Synthesis,1982,p. 325 - 326

23
[ 13754-19-3 ]
[ 58314-42-4 ]
[ 61169-10-6 ]

Reference： [1]Chemical and Pharmaceutical Bulletin,1981,vol. 29,p. 1832 - 1837

24
[ 13754-19-3 ]
[ 701-73-5 ]
[ 103588-31-4 ]

Reference： [1]Synthesis,1985,p. 867 - 870

25
[ 13754-19-3 ]
[ 13037-22-4 ]
[ 103588-32-5 ]

Reference： [1]Synthesis,1985,p. 867 - 870

26
[ 13754-19-3 ]
[ 34956-06-4 ]
[ 103588-33-6 ]

Reference： [1]Synthesis,1985,p. 867 - 870

27
[ 13754-19-3 ]
[ 30683-93-3 ]
[ 103588-34-7 ]

Reference： [1]Synthesis,1985,p. 867 - 870

28
[ 13754-19-3 ]
[ 72856-73-6 ]
[ 77456-44-1 ]

Reference： [1]European Journal of Medicinal Chemistry,1990,vol. 25,p. 467 - 477

29
[ 13754-19-3 ]
[ 72856-73-6 ]
[ 95420-69-2 ]

Reference： [1]Journal of Medicinal Chemistry,1985,vol. 28,p. 717 - 727

30
[ 13754-19-3 ]
[ 76423-99-9 ]
[ 103588-19-8 ]

Reference： [1]Synthesis,1985,p. 867 - 870

31
[ 13754-19-3 ]
[ 83431-63-4 ]
[ 103588-21-2 ]

Reference： [1]Synthesis,1985,p. 867 - 870

32
[ 13754-19-3 ]
[ 103588-18-7 ]
[ 103588-22-3 ]

Reference： [1]Synthesis,1985,p. 867 - 870

33
[ 13754-19-3 ]
[ 201230-82-2 ]
[ 13230-97-2 ]

Reference： [1]Bulletin of the Chemical Society of Japan,1987,vol. 60,p. 1793 - 1800
[2]Phosphorus and Sulfur and the Related Elements,1988,vol. 38,p. 137 - 148

34
[ 13754-19-3 ]
[ 36016-40-7 ]
2,4,6-Trimethyl-benzenesulfonate1,4,5-triamino-pyrimidin-1-ium; [ No CAS ]

Reference： [1]Journal of Chemical Research, Miniprint,1989,p. 1201 - 1218

35
[ 13754-19-3 ]
[ 71254-91-6 ]
[ 120-73-0 ]

Reference： [1]Tetrahedron,1983,vol. 39,p. 3971 - 3980

36
[ 13754-19-3 ]
[ 93515-49-2 ]
[ 103588-35-8 ]

Reference： [1]Synthesis,1985,p. 867 - 870

37
[ 13754-19-3 ]
[ 83431-64-5 ]
[ 103588-20-1 ]

Reference： [1]Synthesis,1985,p. 867 - 870

38
[ 13754-19-3 ]
[ 83769-37-3 ]
6-(1-Fluoro-1-methyl-ethyl)-8H-pteridin-7-one [ No CAS ]

Reference： [1]Journal of Fluorine Chemistry,1989,vol. 44,p. 15 - 24

39
[ 13754-19-3 ]
[ 123-76-2 ]
8a-Methyl-7,8,8a,9-tetrahydro-6H-pyrrolo<2,1-f>purin-6-one [ No CAS ]

Reference： [1]Il Farmaco,1993,vol. 48,p. 1261 - 1269

40
[ 13754-19-3 ]
[ 80823-75-2 ]
[ 127749-70-6 ]

Reference： [1]Journal of Heterocyclic Chemistry,1989,vol. 26,p. 1755 - 1769
[2]Journal of Heterocyclic Chemistry,1989,vol. 26,p. 1755 - 1769

41
[ 13754-19-3 ]
[ 1210-05-5 ]
[ 80484-73-7 ]

Reference： [1]Journal of Organic Chemistry,1982,vol. 47,p. 1578 - 1579

42
[ 13754-19-3 ]
[ 2051-95-8 ]
8a-Phenyl-7,8,8a,9-tetrahydro-6H-pyrrolo<2,1-f>purin-6-one [ No CAS ]

Reference： [1]Il Farmaco,1993,vol. 48,p. 1261 - 1269

43
[ 13754-19-3 ]
[ 407-25-0 ]
[ 2268-12-4 ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1981,p. 2974 - 2977

44
[ 13754-19-3 ]
[ 105-53-3 ]
[ 154124-55-7 ]

Reference： [1]Journal of Heterocyclic Chemistry,1993,vol. 30,p. 283 - 285

45
[ 13754-19-3 ]
[ 366-77-8 ]
8a-(4'-Fluorophenyl)-7,8,8a,9-tetrahydro-6H-pyrrolo<2,1-f>purin-6-one [ No CAS ]

Reference： [1]Il Farmaco,1993,vol. 48,p. 1261 - 1269

46
[ 16008-45-0 ]
[ 13754-19-3 ]
[ 120-73-0 ]

Reference： [1]Journal of Organic Chemistry,1984,vol. 49,p. 4964 - 4969

47
[ 16008-45-0 ]
[ 13754-19-3 ]
[ 64-18-6 ]
[ 120-73-0 ]

Reference： [1]Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry,1984,vol. 38,p. 673 - 678

48
[ 13754-19-3 ]
[ 32786-03-1 ]
(3aR,5aR,8aR,8bS)-2,2,7,7-Tetramethyl-tetrahydro-bis[1,3]dioxolo[4,5-b;4',5'-d]pyran-3a-carboxylic acid (5-amino-pyrimidin-4-yl)-amide [ No CAS ]

Reference： [1]Journal of the Chemical Society. Perkin transactions I,1980,p. 2683 - 2685

49
[ 93135-56-9 ]
[ 13754-19-3 ]
[ 532-20-7 ]

Reference： [1]Journal of Organic Chemistry,1984,vol. 49,p. 4964 - 4969

50
(3aR,4R,7R,7aR)-4-(5-Amino-pyrimidin-4-ylamino)-2,2-dimethyl-tetrahydro-[1,3]dioxolo[4,5-c]pyran-7-ol [ No CAS ]
[ 13754-19-3 ]
[ 67814-68-0 ]

Reference： [1]Journal of Organic Chemistry,1984,vol. 49,p. 4964 - 4969

51
C₈⁽¹⁴⁾CH₁₄N₄O₄ [ No CAS ]
[ 13754-19-3 ]
[ 19214-82-5 ]

Reference： [1]Journal of Organic Chemistry,1984,vol. 49,p. 4964 - 4969

52
[ 95103-63-2 ]
[ 13754-19-3 ]
[ 934-33-8 ]
7,8-dihydro-8-methylpurine [ No CAS ]

Reference： [1]Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry,1984,vol. 38,p. 573 - 578

53
[ 78105-09-6 ]
[ 13754-19-3 ]
[ 934-33-8 ]

Reference： [1]Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry,1982,vol. 36,p. 707 - 712

54
[ 78105-09-6 ]
[ 13754-19-3 ]
[ 934-33-8 ]
7,8-dihydro-8-methylpurine [ No CAS ]

Reference： [1]Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry,1984,vol. 38,p. 573 - 578

55
[ 95103-62-1 ]
[ 13754-19-3 ]
[ 934-33-8 ]
7,8-dihydro-8-methylpurine [ No CAS ]

Reference： [1]Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry,1984,vol. 38,p. 573 - 578

56
[ 95103-65-4 ]
[ 13754-19-3 ]
[ 934-33-8 ]
7,8-dihydro-8-methylpurine [ No CAS ]

Reference： [1]Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry,1984,vol. 38,p. 573 - 578

57
[ 13754-19-3 ]
[ 65-85-0 ]
[ 4776-14-1 ]

Reference： [1]Tetrahedron Letters,2006,vol. 47,p. 2883 - 2886

58
[ 13754-19-3 ]
[ 879-65-2 ]
2-(7<i>H</i>-purin-8-yl)-quinoxaline [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2005,vol. 48,p. 8253 - 8260

59
[ 13754-19-3 ]
[ 708-06-5 ]
1-[(4-aminopyrimidin-5-yl-imino)methyl]naphthalen-2-ol [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry,2006,vol. 14,p. 3758 - 3765

60
[ 13754-19-3 ]
[ 49802-71-3 ]
[ 897446-49-0 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2006,vol. 14,p. 4490 - 4518

61
[ 13754-19-3 ]
[ 51285-26-8 ]
[ 15846-75-0 ]

Reference： [1]Journal of Medicinal Chemistry,2006,vol. 49,p. 511 - 522

62
[ 13754-19-3 ]
[ 16024-82-1 ]
3-(4-amino-pyrimidin-5-yl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one [ No CAS ]

Reference： [1]Arzneimittel-Forschung/Drug Research,2006,vol. 56,p. 665 - 670

63
[ 797047-27-9 ]
[ 13754-19-3 ]
C₈H₁₀N₆O [ No CAS ]

Reference： [1]Tetrahedron Letters,2007,vol. 48,p. 5535 - 5538

64
[ 13754-19-3 ]
[ 63192-57-4 ]
[ 108-39-4 ]
3,3'-pteridine-6,7-diyldiphenol m-cresol salt [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 4279 - 4294

65
[ 13754-19-3 ]
[ 79099-07-3 ]
[ 784155-44-8 ]

Yield	Reaction Conditions	Operation in experiment
		A mixture OF 4, 5-DIAMINOPYRIMIDINE (1.0 g, 9.1 MMOL), N-(5-butoxycarbonyl)-4- piperidone (3.0 g, 15 mmol) and sodium triacetoxyborohydride (1.2 g, 5.6 mmol) in dichloroethane (60 mL) was stirred at room temperature for 3 d. The reaction was partitioned between chloroform (200 mL) and 3N sodium hydroxide (30 ML). After drying over magnesium sulfate, the organic phase was concentrated to give the title compound as a tan gum. MS 294 (M+1)
		A mixture of <strong>[13754-19-3]4,5-diaminopyrimidine</strong> (1.0 g, 9.1 mmol), piperidone (3.0 g, 15 mmol) and sodium triacetoxyborohydride (1.2 g, 5.6 mmol) in dichloroethane (60 mL) was stirred at room temperature for 3 d. The reaction was partitioned between chloroform (200 mL) and 3 Nu sodium hydroxide (30 mL). After drying over magnesium sulfate, the organic phase was concentrated to give the title compound as a tan gum. MS: m/z = 294 (M+l)
	With sodium tris(acetoxy)borohydride; In 1,2-dichloro-ethane; at 20℃; for 72h;	INTERMEDIATE 3 7-Piperidin-4-yl-7,9-dihydro-8iJ"-purin-8-one hydrochlorideStep A. 4-Amino-5-[(l -fert-butoxycarbonylpiperidm-4-yl)amino)pyrimidine; A mixture of <strong>[13754-19-3]4,5-diaminopyrimidine</strong> (1.0 g, 9.1 mmol), JV-(tert-butoxycarbonyl)- 4-piperidone (3.0 g, 15 mmol) and sodium triacetoxyborohydride (1.2 g, 5.6 mmol) in dichloroethane (60 mL) was stirred at room temperature for 3 d. The reaction was partitioned between chloroform (200 mL) and 3 N sodium hydroxide (30 mL). After drying over EPO <DP n="66"/>magnesium sulfate, the organic phase was concentrated to give the title compound as a tan gum. MS 294 (M+l)

With sodium tris(acetoxy)borohydride; In 1,1-dichloroethane; at 20℃; for 72h;

A mixture of <strong>[13754-19-3]4,5-diaminopyrimidine</strong> (1.0 g, 9.1 mmol), N-(fer£-butoxycarbonyl)-4- piperidone (3.0 g, 15 mmol) and sodium triacetoxyborohydride (1.2 g, 5.6 mmol) in dichloroethane (60 mL) was stirred at room temperature for 3 d. The reaction was partitioned between chloroform (200 mL) and 3 Nu sodium hydroxide (30 mL). After drying over magnesium sulfate, the organic phase was concentrated to give the title compound as a tan gum. MS 294 (M+ 1)

Reference： [1]Patent: WO2004/92166,2004,A2 .Location in patent: Page 68
[2]Patent: WO2007/16087,2007,A2 .Location in patent: Page/Page column 52
[3]Patent: WO2006/44504,2006,A1 .Location in patent: Page/Page column 64-65
[4]Patent: WO2006/99268,2006,A2 .Location in patent: Page/Page column 53-54

66
[ 13754-19-3 ]
[ 199861-81-9 ]
[ 21908-53-2 ]
2-{2-[7-chloro-3-(3,5-dimethylphenyl)-2-oxo-6-(9H-purin-8-ylamino)-1,2-dihydroquinolin-4-yloxy]-ethyl}-piperidine-1-carboxylic acid tert-butyl ester [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With hydrogenchloride; ammonia; In methanol; hexane; chloroform; ethyl acetate; toluene;	Step 6.3A 2-{2-[7-chloro-3-(3,5-dimethylphenyl)-2-oxo-6-(9H-purin-8-ylamino)-1,2-dihydroquinolin-4-yloxy]-ethyl}-piperidine-1-carboxylic acid tert-butyl ester To a solution of 2-{2-[7-chloro-3-(3,5-dimethylphenyl)-6-isothiocyanato-2-oxo-1,2-dihydroquinolin-4-yloxy]-ethyl}-piperidine-1-carboxylic acid tert-butyl ester (210 mg in 5 mL toluene) was added 250 mg mercury(II) oxide followed by 130 mg <strong>[13754-19-3]4,5-diaminopyrimidine</strong> and the mixture heated to reflux on an oil bath. After 48 hours, the mixture was cooled to room temperature and the reaction quenched by the addition of 2N hydrochloric acid (4 mL). The solvents were removed in vacuo and the residue treated with 2N ammonia in methanol (10 mL) then concentrated once again. The residue was washed with chloroform and the solids removed by filtration. Concentration of the organics and purification by flash chromatography on silica gel (ethyl acetate:hexane, 1:1; then chloroform:2N ammonia in methanol, 9:1) gave the title compound (10 mg).

Reference： [1]Patent: US6150352,2000,A

67
[ 13754-19-3 ]
[ 623-50-7 ]
[ 934-33-8 ]

Yield	Reaction Conditions	Operation in experiment
		PREPARATION 48 2-Hydromethyl-3H-imidazo[5,4-d]pyrimidine 8.58 g of ethyl glycolate were added to 2.27 g of <strong>[13754-19-3]4,5-diaminopyrimidine</strong>, and the resulting mixture was stirred at 140 C. for 2 hours. At the end of this time, the reaction mixture was freed from ethyl glycolate by distillation under reduced pressure. The residue thus obtained was decolorized by activated charcoal and crystallized by trituration with ethanol, to give 1.81 g of the title compound having Rf=0.27 (on silica gel thin layer chromatography using a 10:1 by volume mixture of ethyl acetate and methanol as the developing solvent).

Reference： [1]Patent: US5624935,1997,A

68
[ 13754-19-3 ]
[ 3947-46-4 ]

Yield	Reaction Conditions	Operation in experiment
73%	With oxalic acid; In hydrogenchloride;	Example 5 Preparation of 6,8-Diaza-1,4-dihydroquinoxaline-2,3-dione (13) A solution of 262 mg (2.38 mmol) of <strong>[13754-19-3]4,5-diaminopyrimidine</strong> (12) and 226 mg (2.51 mmol) of oxalic acid in 3 mL of 2N HCl was refluxed for 5 h and cooled to room temperature. The mixture was filtered, washed with water, and dried to leave a brown solid (285 mg, 73%), mp >250 C. 1 H NMR (DMSO-d6), 8.357 (s,1), 8.600 (s,1), 12.062 (s,1), 12.642 (s,1). MS, 164 (M+, 100), 136 (80), 109 (20). HRMS calcd for C6 H4 N4 O2, 164.0330, found 164.0351.

Reference： [1]Patent: US5620978,1997,A

69
[ 13754-19-3 ]
[ 4519-39-5 ]
8-(2,3-difluorophenyl)-purine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		4,5-Diaminopyrimidine (1) (4.5 g, 0.04 moles) and 2,3-difluorobenzoic acid (2) (6.95 g, 0.044 moles) were suspended in 100 mL of Eaton's Acid. The reaction mixture was heated in an oil bath at 190 C. for 2 hours and then poured into 800 mL ice/water. Solid sodium hydroxide was added (59 g, 1.5 moles) to adjust to pH 5, which resulted in the product precipitating from solution. The product was filtered and washed twice with deionized water and air dried. The crude product was recrystallized from water/ethanol resulting in 8 g of pure product (3) (M+1=233). Purine (3) (500 mg, 2.15 mmoles) was dissolved in 10 mL of anhydrous DMF and 1.1 mL of sodium hydroxide solution (10% w/v) was added. 5-(Chloromethyl)-3-(4-chlorophenyl)isoxazole (4) (587 mg, 2.6 mmoles) was added to the above reaction mixture and the solution was stirred at room temperature overnight. The crude product was triturated from water followed by recrystallization from hot ethyl acetate. The precipitate was filtered to yield 30 mg of the gold colored solid 1-((3-(4-chlorophenyl)isoxazol-5-yl)methyl)-8-(2,3-difluorophenyl)-1H-purine 5) in high purity as determined by analytical LC/MS (M+1=429) and 1H NMR (400 MHz, DMSO-d6) delta 5.99 (s, 2H), 7.17 (s, 1H), 7.34 (m, 1H), 7.55 (s, 1H), 7.56 (d, 2H), 7.87 (d, 2H), 8.14 (m, 1H), 9.14 (s, 1H), 9.32 (s, 1H).

Reference： [1]Patent: US2006/52602,2006,A1 .Location in patent: Page/Page column 53-54

70
[ 13754-19-3 ]
[ 445-29-4 ]
[ 878287-56-0 ]

Yield	Reaction Conditions	Operation in experiment
88.5%		A mixture of <strong>[13754-19-3]4,5-diaminopyrimidine</strong> (0.500 g), 2-fluorobenzoic acid (0.700 g) and polyphosphoric acid (25 mL) was heated at 180 C. for 3 hours. Then the reaction mixture was cooled and poured into water (500 mL). The solution was adjusted to pH=8-9 by addition of solid NaOH and the resulting precipitate was collected by filtration, washed with water and dried to give 8-(2-fluorophenyl)-purine (off-white powder, 88.5%). 1H NMR (200 MHz, DMSO-d6) delta 13.79 (br s, 1H, NH), 9.14 (s, 1H, purine-H), 8.95 (s, 1H, purine-H), 8.23 (m, 1H, phenyl-H), 7.73-7.41 (m, 3H, phenyl-H).

Reference： [1]Patent: US2006/52602,2006,A1 .Location in patent: Page/Page column 52

71
[ 13754-19-3 ]
[ 913572-32-4 ]
8-[1-({5-chloro-2-[(2-methylpropyl)oxy]phenyl}methyl)-5-methyl-1H-pyrazol-3-yl]-1H-purine hydrochloride [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		A mixture of <strong>[13754-19-3]4,5-diaminopyrimidine</strong> (55mg, O.deltammol) and methyl 1-({5-chloro-2-[(2- methylpropyl)oxy]phenyl}methyl)-5-methyl-1/-/-pyrazole-3-carboximidoate hydrochloride (186mg, O.deltammol) in acetic acid (4ml) was stirred and refluxed for 4 hours. The solution was cooled, evaporated, the residue dissolved in ethyl acetate/water, basified with 2M sodium hydroxide and the organic phase dried (magnesium sulphate), evaporated and purified by flash chromatography eluting with methanol/ethyl acetate (1 :49). The product EPO <DP n="130"/>was dissolved in methanol, 1 M hydrogen chloride in ether (0.5ml) added and the solution, evaporated to dryness. The residue was triturated with ether to give the title compound as an off-white solid (13mg). LC/MS Rt 2.94, [MH]+ 397.3, 399.2.

Reference： [1]Patent: WO2006/114313,2006,A1 .Location in patent: Page/Page column 127-128

72
[ 13754-19-3 ]
[ 403-43-0 ]
N-(4-amino-5-pyrimidinyl)-4-fluorobenzamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
30 parts (70%)	With pyridine; In water; N,N-dimethyl-formamide;	Example 2 To a stirred mixture of 20.2 parts of <strong>[13754-19-3]4,5-pyrimidinediamine</strong>, 40 parts of pyridine and 144 parts of N,N-dimethylformamide was added dropwise a solution of 24.2 parts of 4-fluorobenzoyl chloride in 36 parts of N,N-dimethylformamide at 10 C. Upon completion, stirring was continued for 30 minutes at room temperature. 600 Parts of water were added. The product was filtered off and dried, yielding 30 parts (70%) of N-(4-amino-5-pyrimidinyl)-4-fluorobenzamide (interm. 11).

Reference： [1]Patent: US5041448,1991,A

73
[ 13754-19-3 ]
aqueous dimethylamine [ No CAS ]
[ 89469-32-9 ]
[ 89469-19-2 ]

Yield	Reaction Conditions	Operation in experiment
27%		EXAMPLE 52 8-(2'-Methoxy-4'-dimethylaminosulfonyl-phenyl)-purine hydrochloride Prepared analogously to Example 51 from 2-methoxy-4-chlorosulfonyl-benzoic acid, aqueous dimethylamine solution, and <strong>[13754-19-3]4,5-diamino-pyrimidine</strong>. The hydrochloride was recrystallized from ethanol/water (4:1). Yield: 27% of theory. M.p.: 230-234 C. Calc.: C, 45.47; H, 4.36; N, 18.94; Cl, 9.60; S, 8.70. Found: C, 45.11; H, 4.66; N, 19.26; Cl, 9.24; S, 8.43.

Reference： [1]Patent: US4582837,1986,A

74
[ 13754-19-3 ]
[ 89469-48-7 ]
[ 89454-46-6 ]

Yield	Reaction Conditions	Operation in experiment
11.2%		EXAMPLE 20 8-(3'-Methoxy-4'-methanesulfonylamino-phenyl)-purine Prepared analogously to Example 14 from <strong>[13754-19-3]4,5-diaminopyrimidine</strong> and 3-methoxy-4-methanesulfonylamino-benzoic acid. Yield: 11.2% of theory. M.p.: >250 C. C13 H13 N5 O3 S: (319.35)--Calc.: C, 48.89; H, 4.10; N, 21.93; S, 10.04. Found: C, 48.31; H, 4.45; N, 21.74; S, 10.80.

Reference： [1]Patent: US4582837,1986,A

75
[ 13754-19-3 ]
[ 89469-32-9 ]
2-(2'-Methoxy-4'-chlorosulfonyl-phenyl)-purine hydrochloride [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		EXAMPLE D 2-(2'-Methoxy-4'-chlorosulfonyl-phenyl)-purine hydrochloride Prepared analogously to Example C from 2.5 gm of 2-methoxy-4-chlorosulfonyl benzoic acid and 2.4 gm of <strong>[13754-19-3]4,5-diamino-pyrimidine</strong> (crystalline product obtained from dihydorchloride and 1 mol of common salt) by refluxing for eight hours. The solid crude product was processed further without any purification.

Reference： [1]Patent: US4582837,1986,A

76
[ 13754-19-3 ]
[ 89469-32-9 ]
[ 89469-17-0 ]

Yield	Reaction Conditions	Operation in experiment
65%	With ammonium hydroxide; ammonia;	EXAMPLE 50 8-(2'-Methoxy-4'-aminosulfonyl-phenyl)-purine Prepared analogously to Example 47 from 2-methoxy-4-chlorosulfonyl-benzoic acid, ammonia, and <strong>[13754-19-3]4,5-diaminopyrimidine</strong> (crystals obtained from the dihycrochloride with 1 mol of common salt). After being reacted with aqueous ammonia, the reaction solution was evaporated down to about one-third, after which the free base was precipitated in the form of crystals. Yield: 65% of theory. M.p.: 270 C. (decomposition). Calc.: C, 47.21; H, 3.63; N, 22.94; S, 10.50. Found: C, 46.95; H, 3.68; N, 22.84; S, 10.50.

Reference： [1]Patent: US4582837,1986,A

77
[ 13754-19-3 ]
[ 89469-44-3 ]
[ 89454-37-5 ]

Yield	Reaction Conditions	Operation in experiment
40.75%		EXAMPLE 16 8-(2'-Methoxy-4'-methanesulfonylamino-phenyl)-purine Prepared analogously to Example 14 from <strong>[13754-19-3]4,5-diaminopyrimidine</strong> and 2-methoxy-4-methanesulfonylamino-benzoic acid. Yield: 40.75% of theory. M.p.: 237-238 C. C13 H13 N5 O3 S: Calc.: C, 48.89; H, 4.10; N, 21.93; S, 10.94. Found: C, 48.81; H, 4.37; N, 21.88; S, 9.95.

Reference： [1]Patent: US4582837,1986,A

78
[ 13754-19-3 ]
[ 4107-65-7 ]
[ 6192-52-5 ]
8-(2,4-Dimethoxy-phenyl)-purine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In benzene;	Example 1 8-(2,4-Dimethoxy-phenyl)-purine A mixture of 2 g of <strong>[13754-19-3]4,5-diamino-pyrimidine</strong>, 4 g of 2,4-dimethoxy-benzonitrile, 6 g of p-toluene sulfonic acid hydrate, and 40 ml of benzene was heated, whereby the benzene was distilled off. The residue was heated for 30 minutes at 120 C. After cooling the residue was triturated with 2 N ammonia and extracted with ethyl acetate. The ethyl acetate phase was extracted with 2 N hydrochloric acid, the aqueous phase was neutralized and again extracted with ethyl acetate, and subsequently the organic phase was extracted with 2 N sodium hydroxide solution. When the aqueous phase was neutralized, the product was precipitated and recrystallized from water. Yield: 0.15 g (3% of theory), M.P.: 221 C. (decomp).

Reference： [1]Patent: US4299834,1981,A

79
[ 13754-19-3 ]
[ 91-52-1 ]
8-(2,4-Dimethoxy-phenyl)-purine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With trichlorophosphate;	Example 2 8-(2,4-Dimethoxy-phenyl)-purine A mixture of 5.5 g of <strong>[13754-19-3]4,5-diaminopyrimidine</strong> and 10.9 g of 2,4-dimethoxy-benzoic acid was triturated in a mortar. The mixture was added to 100 ml of phosphorus oxychloride and refluxed for one hour. The phosphorus oxychloride was decomposed under stirring into water, and the solution obtained was neutralized with ammonia after filtration. The precipitated product was recrystallized from water and ethanol/cyclohexane (volume ratio of 1:3). Yield: 3.5 g (27% of theory), M.P.: 218-220 C.

Reference： [1]Patent: US4299834,1981,A

80
[ 13754-19-3 ]
[ 915771-21-0 ]
[ 915949-10-9 ]

Yield	Reaction Conditions	Operation in experiment
	With 1,1-Carbodiimide; In propyl cyanide; at 20 - 200℃; for 2h;Microwave irradiation;	1,1-Carbodiimide (620 mg, 3.82 mmol) was added to a solution of 3-[(phenylmethyl)oxy]- 5-[(31S)-tetrahydrofuran-3-yloxy]benzoic acid (1000 mg, 3.18 mmol) in butyronitrile (10 mL). The solution was stirred at RT then <strong>[13754-19-3]4,5-diaminopyrimidine</strong> (351 mg, 3.18 mmol) added and the mixture stirred at 2000C for 2 hours in microwave reactor. The mixture was reduced in vacuo, the residue triturated with MeOH (20 mL) and filtered to give the desired compound as a cream coloured solid (548 mg). 1H NMR (400 MHz, DMSO) delta 1.95 - 2.05 (m, IH), 2.20 - 2.35 (m, IH), 3.70 -4.00 (m, 4H), 5.15 (m, IH), 5.22 (s, 2H), 6.79 (s, IH), 7.30 - 7.60 (m, 7H), 8.91 (s, IH), 9.11 (s, IH), 13.82 (brs, IH); m/z 389 (M+H)+, 387 (M-H)-.

Reference： [1]Patent: WO2006/125958,2006,A1 .Location in patent: Page/Page column 134

81
[ 13754-19-3 ]
C₁₄H₇ClFNO₂ [ No CAS ]
N-(4-amino-5-pyrimidinyl)-3-cyano-4-(4-fluorophenoxy)benzamide [ No CAS ]

Reference： [1]Patent: WO2007/4688,2007,A1 .Location in patent: Page/Page column 25

82
[ 13754-19-3 ]
[ 701-73-5 ]
[ 103588-31-4 ]

Reference： [1]Tetrahedron Letters,2008,vol. 49,p. 992 - 995

83
[ 13754-19-3 ]
[ 126-81-8 ]
[ 1047619-57-7 ]

Yield	Reaction Conditions	Operation in experiment
86%	In toluene;Heating / reflux;	Example 56: synthesis of 10-(2,4-dichloro-phenyl)-7,7-dimethyl-5,6,7,8,10,l l-hexa- hydro-1, 3,5,1 l-tetraaza-dibenzora,d1cyclohepten-9-one (84); A solution of <strong>[13754-19-3]pyrimidine-4,5-diamine</strong> (1 g, 9 mmol) and dimedone (1.27 g, 1 eq) in toluene (60 mL) was refluxed overnight with a Dean-stark apparatus. The reaction mixture was cooled down to room temperature and filtered. The precipitate was washed with isopropylether and dried, yielding 1.8 g (86%) of the desired product 3-(4-amino- pyrimidin-5-ylamino)-5,5-dimethyl-cyclohex-2-enone (83).

Reference： [1]Patent: WO2008/99021,2008,A1 .Location in patent: Page/Page column 56
[2]Bioorganic and Medicinal Chemistry Letters,2009,vol. 19,p. 2492 - 2496

84
[ 13754-19-3 ]
[ 1023694-79-2 ]
[ 1023694-43-0 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2008,vol. 18,p. 2530 - 2535

85
[ 13754-19-3 ]
3-(2'-benzothiazolyl)-6-chloro-2H-1-benzopyran-2-one [ No CAS ]
[ 1214990-29-0 ]

Reference： [1]Phosphorus, Sulfur and Silicon and the Related Elements,2009,vol. 184,p. 2856 - 2869

86
C₁₈H₃₂O₁₆ [ No CAS ]
[ 13754-19-3 ]
3-((3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-((3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)tetrahydro-2H-pyran-2-yloxy)-1-(7H-purin-8-yl)pentane-1,2,4,5-tetraol [ No CAS ]

Reference： [1]Molecules,2010,vol. 15,p. 1340 - 1353

87
[ 13754-19-3 ]
[ 530-62-1 ]
[ 13230-97-2 ]

Yield	Reaction Conditions	Operation in experiment
61%	In 1,4-dioxane; at 90℃; for 48h;	Preparation 77,9-Dihydro-purin-8-oneThe synthetic procedure used in this preparation is outlined below in Scheme H. Pyrimidine-4,5-diamine (1.1 g, 10 mmol) and 1,1'-carbonyl diimidazole 1.78 g, 1.1 mmol) were added to dioxane (15 mL) and the reaction mixture was stirred at 90 C. for 48 hours. The mixture was cooled and the precipitate was recovered by filtration, rinsed with cold dioxane, and dried to give 850 mg (61%) of 7,9-dihydro-purin-8-one.

Reference： [1]Patent: US2010/324069,2010,A1 .Location in patent: Page/Page column 28

88
[ 13754-19-3 ]
(2R)-1-((2S)-3-mercapto-2-methylpropanoyl)pyrrolidine-2-carboxylic acid [ No CAS ]
1-(2-(9H-purin-8-yl)pyrrolidin-1-yl)-3-mercapto-2-methylpropan-1-one [ No CAS ]

Reference： [1]ARKIVOC,2010,vol. 2010,p. 242 - 253

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 13754-19-3 ]

Amines

[ 591-55-9 ]

5-Aminopyrimidine

Similarity: 0.82

[ 118-70-7 ]

Pyrimidine-4,5,6-triamine

Similarity: 0.81

[ 22715-27-1 ]

2,5-Diaminepyrimidine

Similarity: 0.79

[ 452-06-2 ]

7H-Purin-2-amine

Similarity: 0.74

[ 3438-61-7 ]

5-Amino-4-methylpyrimidine

Similarity: 0.73

Related Parent Nucleus of
[ 13754-19-3 ]

Pyrimidines

[ 591-55-9 ]

5-Aminopyrimidine

Similarity: 0.82

[ 118-70-7 ]

Pyrimidine-4,5,6-triamine

Similarity: 0.81

[ 22715-27-1 ]

2,5-Diaminepyrimidine

Similarity: 0.79

[ 3438-61-7 ]

5-Amino-4-methylpyrimidine

Similarity: 0.73

[ 39889-94-6 ]

5-Amino-2-methylpyrimidine

Similarity: 0.71

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 13754-19-3 ] {[proInfo.proName]}

Quality Control of [ 13754-19-3 ]

Related Doc. of [ 13754-19-3 ]

Product Details of [ 13754-19-3 ]

Calculated chemistry of [ 13754-19-3 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 13754-19-3 ]

Application In Synthesis of [ 13754-19-3 ]

[ 13754-19-3 ] Synthesis Path-Upstream 1~21

[ 13754-19-3 ] Synthesis Path-Downstream 1~88

Related Functional Groups of [ 13754-19-3 ]

Amines

Related Parent Nucleus of [ 13754-19-3 ]

Pyrimidines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 13754-19-3 ]

Related Parent Nucleus of
[ 13754-19-3 ]